News that the National Institute for Health and Care Excellence (NICE) has approved the use of Eylea – a further drug to treat wet age-related degeneration (AMD) – has been well received by bodies such as the Royal National Institute for Blind…
Antihypertensives, including angiotensin-converting-enzyme (ACE) inhibitors and beta blockers, may have the additional benefit of lowering the risk of both forms of age-related macular degeneration (AMD), a large retrospective study shows. Dr. Partho Kalyani, a fellow in the Department of Ophthalmology…
The long-awaited results of Age-Related Eye Disease Study 2 (AREDS2) have shown that adding omega-3 fatty acids and other nutrients to standard antioxidant vitamins doesn’t give any added protection against age-related macular degeneration (AMD). The disease is reported as the…